Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alvotech - Ordinary Shares
(NQ:
ALVO
)
12.04
+0.10 (+0.84%)
Streaming Delayed Price
Updated: 10:53 AM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
6,358
Open
12.04
Bid (Size)
11.95 (1)
Ask (Size)
12.04 (4)
Prev. Close
11.94
Today's Range
11.92 - 12.04
52wk Range
8.290 - 18.00
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
Today 6:30 EDT
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Closing of Private Debt Financing
July 11, 2024
From
Alvotech
Via
GlobeNewswire
Performance
YTD
+5.99%
+5.99%
1 Month
-10.68%
-10.68%
3 Month
-9.68%
-9.68%
6 Month
-15.09%
-15.09%
1 Year
+19.56%
+19.56%
More News
Read More
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
July 10, 2024
Via
MarketBeat
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
July 02, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Issues New Shares to Holders of Convertible Bonds
July 01, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
July 01, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Receives Conversion Notices for Majority of Convertible Bonds
June 26, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe
June 18, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech and STADA add to strategic alliance through denosumab partnership
June 11, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Strategic Refinancing Agreement
June 07, 2024
From
Alvotech
Via
GlobeNewswire
2 Generic Drug Makers With Growing Runways
May 31, 2024
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
May 29, 2024
From
Alvotech
Via
GlobeNewswire
ALVO Stock Earnings: Alvotech Misses EPS for Q1 2024
May 21, 2024
Via
InvestorPlace
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
May 21, 2024
From
Alvotech
Via
GlobeNewswire
Stocks Hold Steady On Mixed Fed Remarks, First Solar Rallies, Bitcoin Falls Below $70,000: What's Driving Markets Tuesday?
May 21, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
May 21, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
May 21, 2024
From
Alvotech
Via
GlobeNewswire
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
May 20, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
May 20, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)
May 13, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
May 02, 2024
From
Alvotech
Via
GlobeNewswire
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
April 30, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
April 30, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
April 24, 2024
From
Alvotech
Via
GlobeNewswire
Fifth Third Bancorp Reports Upbeat Earnings, Joins Metropolitan Bank Holding, Paramount Global And Other Big Stocks Moving Higher On Friday
April 19, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.